Fatigue is a particularly vague, yet significant symptom, which is commonly encountered in primary care. It affects a wide range of patients and has many causes. With an ageing population, fatigue is more likely to be multifactorial towards the end of a person’s life, and this can provide challenges in recognition and management. Patients are often incapacitated due to their fatigue and helping to manage it can lead to an improved quality of life. This article aims to briefly summarise the symptoms of fatigue, how to recognise it and the various causes. Current literature on the management of fatigue in end-of-life care, including pharmacological options, is critically reviewed.
Get full access to this article
View all access options for this article.
References
1.
BowerJ (2007) Cancer-related fatigue: Links with inflammation in cancer patients and survivors. Brain, Behavior and Immunity21(7): 863–871. DOI: 10.1016/j.bbi.2007.03.013.
2.
BrueraEDriverLBarnesE, et al.(2003) Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. Journal of Clinical Oncology21(23): 4439–4443. DOI: 10.1200/JCO.2003.06.156.
3.
ChakrabartyJVidyasagarMFernandesD, et al.(2015) Effectiveness of pranayama on cancer-related fatigue in breast cancer patients undergoing radiation therapy: A randomized controlled trial. International Journal of Yoga8(1): 47–53. DOI: 10.4103/0973-6131.146062.
4.
FineR (2001) Depression, anxiety, and delirium in the terminally ill patient. Proceedings (Baylor University Medical Center)14(2): 130–133. DOI: 10.1080/08998280.2001.11927747.
5.
FisherMDaviesCLacyH, et al.(2018) Oncology Section EDGE Task Force on Cancer: Measures of cancer-related fatigue—a systematic review. Rehabilitation Oncology36(2): 93–105. DOI: 10.1097/01.REO.0000000000000124.
GutsteinH (2001) The biologic basis of fatigue. Cancer92(6): 1678–1683. DOI: 10.1002/1097-0142(20010915)92:6+<1678:: AID-CNCR1496>3.0.CO;2-R.
8.
HofmanMRyanJFigueroa-MoseleyC, et al.(2007) Cancer-related fatigue: The scale of the problem. The Oncologist12(1): 4–10. DOI: 10.1634/theoncologist.12-S1-4.
9.
Horng-ShiuannWMcSweeneyM (2007) Cancer-related fatigue: “It's so much more than just being tired.”. European Journal of Oncology Nursing11(2): 117–125. DOI: 10.1016/j.ejon.2006.04.037.
10.
KnightKWadeSBalducciL (2004) Prevalence and outcomes of anemia in cancer: A systematic review of the literature. The American Journal of Medicine5(116): 11S–26S. DOI: 10.1016/j.amjmed.2003.12.008.
11.
LeonardJEvansMBrownM, et al.(2010) What is fatigue? Pathological and nonpathological fatigue. PM and R2(5): 327–331. DOI: 10.1016/j.pmrj.2010.03.028.
12.
MarshallKLoeligerJNolteL (2019) Prevalence of malnutrition and impact on clinical outcomes in cancer services: A comparison of two time points. Clinical Nutrition38(2): 644–651. DOI: 10.1016/j.clnu.2018.04.007.
13.
MehnertAHartungTFriedrichM, et al.(2018) One in two cancer patients is significantly distressed: Prevalence and indicators of distress. Psycho-Oncology27(1): 75–82. DOI: 10.1002/pon.4464.
14.
MillerAAncoli-IsraelSBowerE (2008) Neuroendocrine-immune mechanisms of behavioural comorbidities in patients with cancer. Journal of Clinical Oncology26(6): 971–982. DOI: 10.1200/JCO.2007.10.7805.
15.
Minton O, Richardson A, Sharpe M, et al. (2010) Drug therapy for the management of cancer-related fatigue. Cochrane Database of Systematic Reviews 7: art. no.: CD006704. DOI: 10.1002/14651858.CD006704.pub3.
16.
MuscaritoliMLuciaSFarcomeniA, et al.(2017) Prevalence of malnutrition in patients at first medical oncology visit: The PreMiO study. Oncotarget8(45): 79884–79896. DOI: 10.18632/oncotarget. 20168.
PearsonEMorrisMStefanoM, et al.(2016) Interventions for cancer-related fatigue: A scoping review. European Journal of Cancer Care27(1): e12516DOI: 10.1111/ecc.12516.
19.
QuDZhangZYuX, et al.(2015) Psychotropic drugs for the management of cancer-related fatigue: A systematic review and meta-analysis. European Journal of Cancer Care25(6): 970–979. DOI: 10.1111/ecc.12397.
SarhillNWalshDNelsonK, et al.(2001) Methylphenidate for fatigue in advanced cancer: A prospective open-label pilot study. The American Journal of Hospice and Palliative Care18(3): 187–192. DOI: 10.1177/104990910101800310.
22.
SteinKMartinSHannD, et al.(1998) A multidimensional measure of fatigue for use with cancer patients. Cancer Practice6(3): 143–152. DOI: 10.1046/j.1523-5394.1998. 006003143.x.
23.
TohYTanCYeoA, et al.(2019) Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study. Journal of Cellular and Molecular Medicine23(6): 4281–4289DOI: 10.1111/jcmm.14319.
24.
WuCZhengYDuanY, et al.(2019) Nonpharmacological interventions for cancer-related fatigue: A systematic review and Bayesian network meta-analysis. Worldviews on Evidence-Based Nursing16(2): 102–110. DOI: 10.1111/wvn.12352.
25.
Xiao C, Smith A, Karen C, et al. (2018) Epigenetic mechanisms of inflammation and fatigue in patients with cancer. In Sigma Theta Tau International's 29th international nursing research congress. Available at: https://sigma.nursingrepository.org/handle/10755/624460 (accessed 27 June 2019).
26.
YennurajalingamSFrisbee-HumeSPalmerJ, et al.(2013) Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. Journal of Clinical Oncology31(25): 3076–3082. DOI: 10.1200/JCO.2012.44.4661.
